About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
ISSN 0300-9092 (Print)
ISSN 2412-5679 (Online)
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2026№6

Real-world clinical use of the domestic medicinal product dienogest 2 mg in patients with endometriosis requiring hormonal therapy

DOI
https://dx.doi.org/10.18565/aig.2026.148

Andreeva E.N., Absatarova Yu.S.

1) Endocrinology Research Centre, Ministry of Health of Russia, Moscow, Russia; 2) Russian University of Medicine, Ministry of Health of Russia, Moscow, Russia

Endometriosis is a chronic disease that dramatically worsens a woman's quality of life and impacts her fertility. Selection of appropriate therapy for stabilizing the process and preventing its progression is a challenging clinical task for gynecologists, especially when surgical treatment is not indicated. In recent years, the use of progestogens, and in particular dienogest, has demonstrated a sustained positive effect on various manifestations of this disease.
Objective. To study the positive effect of the use, tolerability and adherence to each “DlyaJens metri” drug (dienogest 2 mg) in patients with endometriosis requiring hormonal therapy.
Materials and methods. The observational study comprised 740 patients aged 20–45 with stages I–II of endometriosis. The analysis of menstrual bleeding patterns, dysmenorrhea severity, changes in body mass index (BMI), adverse reaction rates, adherence, and patient and physician satisfaction was conducted.
Results. During the therapy we observed a significant reduction in the frequency of heavy menstrual bleeding, as well as its duration, and various manifestations of pain syndrome (dysmenorrhea, dyspareunia, chronic pelvic pain). After 6 months of treatment only 16.2% of women patients complained of endometriosis-associated symptoms. No clinically significant changes in weight or BMI were identified in patients taking “DlyaJens metri” drug throughout the study. We also noted high treatment satisfaction among both physicians and patients. The low incidence of adverse reactions confirms the safety of long-term dienogest therapy.
Conclusion. Our study demonstrated the efficacy and high satisfaction rates of the “DlyaJens metri” Russian dienogest drug among patients with endometriosis during a six-month follow-up in a routine clinical practice. Furthermore, the low incidence of adverse reactions and the absence of weight and libido changes ensured high adherence to such hormone therapy.

Authors’ contributions. Andreeva E.N., Absatarova Yu.S. – study concept and design, data collection and analysis, statistical processing, manuscript writing and editing. All authors approved the final version of the article before publication and agreed to bare responsibility for all aspects of the work, implying proper study of the issues related to the accuracy or integrity of any part of the work.
Conflicts of interest. The authors declare no obvious or potential conflicts of interest related to the content of this article.
Funding. The observational study “Lileya” was initiated and sponsored by the Pharmasyntez Group.
Generative Artificial Intelligence. No artificial intelligence was used when conducting this article.
Patient Consent for Publication. All patients provided informed consent for the publication of their data.
Authors' Data Sharing Statement. The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator.
For citation: Andreeva E.N., Absatarova Yu.S. Real-world clinical use of the domestic medicinal product 
dienogest 2 mg in patients with endometriosis requiring hormonal therapy.
  Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2026; (6): 184-194 (in Russian)
https://dx.doi.org/10.18565/aig.2026.148

Keywords

I–II stage endometriosis
use of gestagens
therapy with 2 mg dienogest
high treatment satisfaction
low rate of unfavourable reactions
DlyaJens metri
long-term treatment safety
Full text (in Russian)

References

  1. Фролова И.Л., Цахилова С.Г., Смирнова Л.Е., Насрединова В.В. Современные аспекты эндометриоза (обзор литературы). Проблемы репродукции. 2019; 25(5): 30-5. https://dx.doi.org/10.17116/repro20192505130 [Frolova I.L., Tsakhilova S.G., Smirnova L.E., Nasredinova V.V. Modern aspects of endometriosis (literature review). Russian Journal of Human Reproduction. 2019; 25(5): 30-5 (in Russian). https://dx.doi.org/10.17116/repro20192505130].
  2. Улумбекова Г.Э., Худова И.Ю. Оценка демографического, социального и экономического эффекта применения гормональной терапии при эндометриозе и аномальных маточных кровотечениях. ОРГЗДРАВ: новости, мнения, обучение. Вестник ВШОУЗ. 2022; 8(1): 82-113. https://dx.doi.org/10.33029/2411-8621-2022-8-1-82-113 [Ulumbekova G.E., Khudova I.Yu. Demographic, social and economic effects of hormonal therapy in endometriosis and abnormal uterine bleeding. HEALTHCARE MANAGEMENT: News, Views, Education. Bulletin of VSHOUZ. 2022; 8(1): 82-113 (in Russian). https://dx.doi.org/10.33029/2411-8621-2022-8-1-82-113].
  3. Артымук Н.В., Данилова Л.Н., Тачкова О.А. Эндометриоз-ассоциированное бесплодие. Клинико-анамнестические особенности. Доктор.Ру. 2022; 21(1): 34-8. https://dx.doi.org/10.31550/1727-2378-2022-21-1-3438 [Artymuk N.V., Danilova L.N., Tachkova O.A. Endometriosis-associated infertility. Clinical and anamnestic characteristics. Doctor.Ru. 2022; 21(1): 34-8 (in Russian). https://dx.doi.org/10.31550/1727-2378-2022-21-1-34-38].
  4. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. 2024. [Ministry of Health of the Russian Federation. Clinical guidelines. Endometriosis. 2024 (in Russian)].
  5. Радзинский В.Е., Оразов М.Р., ред. Бесплодие и эндометриоз. Версии и контраверсии. М.: StatusPraesens; 2019. 208 с. [Radzinsky V.E., Orazov M.R., eds. Infertility and endometriosis. Versions and controversies. Moscow: StatusPraesens; 2019. 208 p. (in Russian)].
  6. Uranga-Romano J.G., Hernández-Valencia M., Zárate A., Basavilvazo-Rodríguez M.A. Dienogest usefulness in pelvic pain due to endometriosis: a meta-analysis of its effectiveness. Rev. Med. Inst. Mex. Seguro Soc. 2017; 55(4): 452-5. Spanish.
  7. Barra F., Scala C., Leone Roberti Maggiore U., Ferrero S. Long-term administration of dienogest for the treatment of pain and intestinal symptoms in patients with rectosigmoid endometriosis. J. Clin. Med. 2020; 9(1): 154. https://dx.doi.org/10.3390/jcm9010154
  8. Leonardo-Pinto J.P., Benetti-Pinto C.L., Angerame Yela D. When solving dyspareunia is not enough to restore sexual function in women with deep infiltrating endometriosis treated with dienogest. J. Sex Marital Ther. 2019; 45(10): 44-9. https://dx.doi.org/10.1080/0092623X.2018.1474411
  9. Xholli A., Filip G., Previtera F., Cagnacci A. Modification of endometrioma size during hormone therapy containing dienogest. Gynecol. Endocrinol. 2019; 36(5): 1-5. https://dx.doi.org/10.1080/09513590.2019.1703942
  10. Pérez-Gómez N., Martínez-Zamora M.Á., Carmona F., Novalbos J., Abad-Santos F., Koller D. et al. An overview of endometriosis and potential pharmacogenetic targets. Pharm. Res. 2026; 43: 605-18. https://dx.doi.org/10.1007/s11095-026-04049-9
  11. Доброхотова Ю.Э., Маркова Э.А., Хлынова С.А., Нариманова М.Р. Эндометриоз. Обзор клинического протокола под разным углом зрения (дискуссия). РМЖ. Мать и дитя. 2024; 7(2): 89-97. https://dx.doi.org/10.32364/2618-8430-2024-7-2-1 [Dobrokhotova Yu.E., Markova E.A., Khlynova S.A., Narimanova M.R. Endometriosis. Сlinical protocol review from different angles (discussion). Russian Journal of Woman and Child Health. 2024; 7(2): 89-97 (in Russian). https://dx.doi.org/10.32364/2618-8430-2024-7-2-1].
  12. Liu J., Wu D., Sun J. Differences in response to dienogest therapy among different phenotypes of endometriosis: a single-center retrospective cohort analysis. Medicine (Baltimore). 2026; 105(7): e47624. https://dx.doi.org/10.1097/MD.0000000000047624
  13. Ярмолинская М.И., Флорова М.С. Возможности терапии диеногестом 2 мг у больных наружным генитальным эндометриозом. Проблемы репродукции. 2017; 23(1): 70-9. https:/dx./doi.org/10.17116/repro201723170-79 [Iarmolinskaia M.I., Florova M.S. The possibility of treatment with dienogest 2 mg in patients with genital endometriosis. Russian Journal of Human Reproduction. 2017; 23(1): 70-9 (in Russian). https:/dx.doi.org/10.17116/repro201723170-79].
  14. Эседова А.Э., Меджидова А.М. Аденомиоз и бесплодие. Подходы к лечению. РМЖ. Мать и дитя. 2021; 4(2): 110-4. https://dx.doi.org/10.32364/2618-8430-2021-4-2-110-114 [Esedova A.E., Medzhidova A.M. Adenomyosis and infertility. Management strategies. Russian Journal of Woman and Child Health. 2021; 4(2): 110-4 (in Russian). https:/dx.doi.org/10.32364/2618-8430-2021-4-2-110-114].
  15. Kathrada F., Van Eyk A., Chauke L. Global variability in the clinical presentation of endometriosis: a scoping review. Women Health. 2025; 65(10): 871-82. https://dx.doi.org/10.1080/03630242.2026.2628763
  16. Адамян Л.В., Протасова А.Э., Асатурова А.В., Раскин Г.А. Эндометриоз-ассоциированные заболевания, эндометриоз и рак: что общего? Проблемы репродукции. 2022; 28(1): 65-74. https://dx.doi.org/10.17116/repro20222801165 [Adamyan L.V., Protasova A.E., Asaturova A.V., Raskin G.A. Endometriosis associated diseases, endometriosis and cancer: what is in common? Russian Journal of Human Reproduction. 2022; 28(1): 65-74 (in Russian). https://dx.doi.org/10.17116/repro20222801165].
  17. Чернуха Г.Е., Пронина В.А. Коморбидность эндометриоза и ее клиническое значение. Акушерство и гинекология. 2023; 1: 27-34. https://dx.doi.org/10.18565/aig.2022.252 [Chernukha G.E., Pronina V.A. Comorbidity of endometriosis and its clinical significance. Obstetrics and Gynecology. 2023; (1): 27-34 (in Russian). https://dx.doi.org/10.18565/aig.2022.252].
  18. Джобава Э.М., Кнышева И.Г., Артизанова Д.П. Дефицит железа в практике врача-гинеколога: эффективность терапии. Акушерство, Гинекология и Репродукция. 2023; 17(2): 202-9. https://dx.doi.org/10.17749/2313-7347/ob.gyn.rep.2023.402 [Dzhobava E.M., Knysheva I.G., Artizanova D.P. Iron deficiency in the practice of a gynecologist: therapeutic efficacy. Obstetrics, Gynecology and Reproduction. 2023; 17(2): 202-9 (in Russian). https://dx.doi.org/10.17749/2313-7347/ob.gyn.rep.2023.402].
  19. De Corte P., Klinghardt M., von Stockum S., Heinemann K. Time to diagnose endometriosis: current status, challenges and regional characteristics - a systematic literature review. BJOG. 2024; 132(2): 118-30. https://dx.doi.org/10.1111/1471-0528.17973
  20. de Souza Gaio G., Kemczenski F., Fernandes Oliveira Amador W., Farias C.F., Chagas J. Clinical effectiveness of progestogens compared to combined oral contraceptive pills in the treatment of endometriosis: a systematic review and meta-analysis. Eur. J. Obstet. Gynecol Reprod. Biol. 2025; 306(6): 219-25. https://dx.doi.org/10.1016/j.ejogrb.2025.01.033
  21. Chen I., Kives S., Zakhari A., Nguyen D.B., Goldberg H.R., Choudhry A.J. et al. Progestagens for pain symptoms associated with endometriosis. Cochrane Database Syst. Rev. 2025; 10(10): CD002122. https://dx.doi.org/10.1002/14651858.CD002122.pub3
  22. García-Sáenz M., Ibarra-Salce R., Pozos-Varela F.J., Mena-Ureta T.S., Flores-Villagómez S., Santana-Mata M. et al. Understanding progestins: from basics to clinical applicability. J. Clin. Med. 2023; 12(10): 3388. https://dx.doi.org/10.3390/jcm12103388

Received 29.04.2026

Accepted 05.06.2026

About the Authors

Elena N. Andreeva, Dr. Med. Sci., Professor, endogin@mail.ru, SPIN-code: 1239-2937, https://orcid.org/0000-0001-8425-0020
Yulia S. Absatarova, PhD, korsil2008@yandex.ru, SPIN-code: 2200-9464, https://orcid.org/0000-0003-0696-5367
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.